Literature DB >> 32959081

Factors associated with in-hospital mortality and adverse outcomes during the vulnerable post-discharge phase after the first episode of acute heart failure: results of the NOVICA-2 study.

Ana García Sarasola1, Miguel Alberto Rizzi2, Aitor Alquezar Arbé1, Sergio Herrera Mateo1, Víctor Gil3, Pere Llorens4, Javier Jacob5, Francisco Javier Martín-Sánchez6, Pablo Herrero Puente7, Rosa Escoda3, Begoña Espinosa4, Àlex Roset5, Raquel Torres-Gárate8, José Torres-Murillo9, Ana B Mecina10, María Pilar López-Díez11, José María Álvarez Pérez11, Josep Tost12, Eva Salvo13, María Luisa López-Grima14, Cristina Gil15, María Mir16, Frank Rutzinska15, Ovidiu Chioncel16, Òscar Miró3.   

Abstract

OBJECTIVE: To identify patients at risk of in-hospital mortality and adverse outcomes during the vulnerable post-discharge period after the first acute heart failure episode (de novo AHF) attended at the emergency department.
METHODS: This is a secondary review of de novo AHF patients included in the prospective, multicentre EAHFE (Epidemiology of Acute Heart Failure in Emergency Department) Registry. We included consecutive patients with de novo AHF, for whom 29 independent variables were recorded. The outcomes were in-hospital all-cause mortality and all-cause mortality and readmission due to AHF within 90 days post-discharge. A follow-up check was made by reviewing the hospital medical records and/or by phone.
RESULTS: We included 3422 patients. The mean age was 80 years, 52.1% were women. The in-hospital mortality was 6.9% and was independently associated with dementia (OR = 2.25, 95% CI = 1.62-3.14), active neoplasia (1.97, 1.41-2.76), functional dependence (1.58, 1.02-2.43), chronic treatment with beta-blockers (0.62, 0.44-0.86) and severity of decompensation (6.38, 2.86-14.26 for high-/very high-risk patients). The 90-day post-discharge combined endpoint was observed in 19.3% of patients and was independently associated with hypertension (HR = 1.40, 1.11-1.76), chronic renal insufficiency (1.23, 1.01-1.49), heart valve disease (1.24, 1.01-1.51), chronic obstructive pulmonary disease (1.22, 1.01-1.48), NYHA 3-4 at baseline (1.40, 1.12-1.74) and severity of decompensation (1.23, 1.01-1.50; and 1.64, 1.20-2.25; for intermediate and high-/very high-risk patients, respectively), with different risk factors for 90-day post-discharge mortality or rehospitalisation.
CONCLUSIONS: The severity of decompensation and some baseline characteristics identified de novo AHF patients at increased risk of developing adverse outcomes during hospitalisation and the vulnerable post-discharge phase, without significant differences in these risk factors according to patient age at de novo AHF presentation.

Entities:  

Keywords:  De novo acute heart failure; Emergency department; Mortality; Rehospitalisation; Risk factors; Vulnerable phase

Year:  2020        PMID: 32959081     DOI: 10.1007/s00392-020-01710-0

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  7 in total

1.  Is the MEESSI-AHF score for Multiple Estimation of risk based on the Spanish Emergency department Score in patients with Acute Heart Failure an effective basis for discharging patients with AHF?

Authors:  Josep Masip
Journal:  Emergencias       Date:  2019-02       Impact factor: 3.881

2.  Risk assessment in emergency department patients with acute heart failure: We need to reach beyond our clinical judgment.

Authors:  Pere Llorens
Journal:  Emergencias       Date:  2018 Abr       Impact factor: 3.881

3.  Acute heart failure: Understanding the patient is essential.

Authors:  Francesc Formiga; David Chivite
Journal:  Emergencias       Date:  2018-06       Impact factor: 3.881

4.  Impact of geriatric assessment variables on 30-day mortality among older patients with acute heart failure.

Authors:  Francisco Javier Martín-Sánchez; Esther Rodríguez-Adrada; María Teresa Vidán; Pablo Díez Villanueva; Guillermo Llopis García; Juan González Del Castillo; Miguel Alberto Rizzi; Aitor Alquézar; Sergio Herrera Mateo; Pascual Piñera; José Andrés Sánchez Nicolás; Paula Lázaro Aragues; Pere Llorens; Pablo Herrero; Javier Jacob; Víctor Gil; Cristina Fernández; Héctor Bueno; Òscar Miró
Journal:  Emergencias       Date:  2018-06       Impact factor: 3.881

5.  Patients with acute heart failure discharged from the emergency department and classified as low risk by the MEESSI score (multiple risk estimate based on the Spanish emergency department scale): prevalence of adverse events and predictability.

Authors:  Òscar Miró; Víctor Gil; Xavier Rosselló; Francisco Javier Martín-Sánchez; Pere Llorens; Javier Jacob; Pablo Herrero; Sergio Herrera Mateo; Fernando Richard; Rosa Escoda; Marta Fuentes; Enrique Martín Mojarro; Lluís Llauger; Héctor Bueno; Stuart Pocock
Journal:  Emergencias       Date:  2019-02       Impact factor: 3.881

6.  Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study.

Authors:  Carlo Mario Lombardi; João Pedro Ferreira; Valentina Carubelli; Stefan D Anker; John G Cleland; Kenneth Dickstein; Gerasimos Filippatos; Chim C Lang; Leong L Ng; Piotr Ponikowski; Nilesh J Samani; Dirk J van Veldhuisen; Faiez Zannad; Adriaan Voors; Marco Metra
Journal:  Clin Res Cardiol       Date:  2020-01-29       Impact factor: 5.460

Review 7.  Cognitive impairment in heart failure patients.

Authors:  Laura Leto; Mauro Feola
Journal:  J Geriatr Cardiol       Date:  2014-12       Impact factor: 3.327

  7 in total
  2 in total

Review 1.  [Update on diagnostics and treatment of heart failure].

Authors:  Jan Wintrich; Ann-Kathrin Berger; Yvonne Bewarder; Insa Emrich; Jonathan Slawik; Michael Böhm
Journal:  Herz       Date:  2021-08-31       Impact factor: 1.740

Review 2.  Timely and individualized heart failure management: need for implementation into the new guidelines.

Authors:  Amr Abdin; Johann Bauersachs; Norbert Frey; Ingrid Kindermann; Andreas Link; Nikolaus Marx; Mitja Lainscak; Jonathan Slawik; Christian Werner; Jan Wintrich; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2021-05-13       Impact factor: 5.460

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.